AB Science (AB) Reports Survival Data for ALS Drug Masitinib

AB Science (AB) released new survival data regarding its drug masitinib for ALS treatment. The reported data suggests a potential improvement in patient outcomes, though specific figures related to survival rates were not disclosed in this announcement. This development could influence the company's stock price and investor interest, particularly if further clinical trial results support these findings. The ALS drug market is competitive, and advancements in treatment options may significantly impact AB's market position.